An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs LBL-024 (Primary) ; Bevacizumab; Carboplatin; Docetaxel; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Substudy 01(NSCLC)
- Sponsors Nanjing Leads Biolabs
- 23 Jan 2025 New trial record